Get a proposal

SCHIZOPHRENIA · White paper

Schizophrenia Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About schizophrenia — and why its trials are hard

Schizophrenia is a chronic, severe psychiatric disorder marked by positive symptoms (hallucinations, delusions, disorganized thinking), negative symptoms (affective flattening, avolition, anhedonia) and cognitive deficits, typically emerging in late adolescence or early adulthood. It affects roughly 24 million people worldwide (about 0.32% of the population) and carries heritability estimated near 80%, alongside dopamine, glutamate and serotonin dysregulation. For decades pharmacotherapy relied on typical and atypical antipsychotics that block dopamine D2 receptors; clozapine remains uniquely effective in treatment-resistant disease and in reducing suicidality. In 2024 the FDA approved xanomeline-trospium (Cobenfy), the first agent acting through a non-D2, muscarinic (M1/M4) mechanism, a landmark shift in a field long dominated by dopamine antagonism. Clinical trials center on PANSS/BPRS symptom change but are challenged by high and variable placebo response, symptom heterogeneity, subjective self-report, cognitive-measurement complexity and long follow-up for relapse endpoints, contributing to a high historical failure rate for novel mechanisms.

Indication
Schizophrenia
ICD-10-CM
F20.9 — Schizophrenia, unspecified

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
Clozapine (Clozaril) 1989Treatment-resistant schizophrenia; reduction of recurrent suicidal behaviorPivotal clozapine vs chlorpromazine trial; InterSePT (vs olanzapine)BPRS/CGI-S response; time to significant suicide attemptResponse rate 30% (clozapine) vs 4% (chlorpromazine); BPRS change -16 vs -5 (p<0.001)
Risperidone (Risperdal / Risperdal Consta) 1993Schizophrenia (oral and long-acting injectable)12-week placebo-controlled trial (Risperdal Consta)PANSS total score changeSignificant PANSS improvement vs placebo at 25/50/75 mg doses
Olanzapine (Zyprexa) 1996Acute and maintenance schizophrenia (adults and adolescents)6-week placebo-controlled trials; longer-term relapse-prevention trialPANSS/BPRS total; time to relapse10 mg/day superior to placebo on PANSS/BPRS; superior relapse prevention (trial stopped early for excess placebo relapses)
Quetiapine (Seroquel / Seroquel XR) 1997Acute and maintenance schizophrenia6-week fixed-dose placebo-controlled trial; maintenance relapse trialPANSS total change; time to relapsePANSS change -30.9 (XR 600 mg) vs -18.8 placebo; significantly longer time to relapse (relapse = >=30% PANSS increase)
Aripiprazole (Abilify) 2002Schizophrenia (D2/5-HT1A partial agonist); LAI formulations availableMultiple 4-6 week placebo-controlled trials; 26-week relapse trialPANSS total change; time to relapsePANSS change ~-15 (10-15 mg) vs ~-2 to -5 placebo; 15 mg/day significantly delayed relapse
Xanomeline-trospium (Cobenfy) 2024Schizophrenia in adults; first-in-class M1/M4 muscarinic agonist (non-D2 mechanism)EMERGENT-2 / EMERGENT-3 (5-week Phase 3)Change in PANSS total score at Week 5EMERGENT-2: PANSS -21.2 vs -11.6 placebo, treatment difference approximately -9.6 (p<0.0001)

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in schizophrenia development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
Pomaglumetad methionil (LY2140023) — Eli Lilly Phase 2/3 programFailed to separate from placebo on PANSS; development discontinuedmGluR2/3 agonist mechanism did not confirm efficacy; high placebo response and patient heterogeneity
Bitopertin — Roche Phase 3 (negative-symptom program)Did not meet primary endpoint for negative symptoms as adjunctive therapyGlycine reuptake (GlyT1) inhibition failed to translate to clinical benefit; difficulty measuring negative-symptom change
Roluperidone (MIN-101) — Phase 3 negative-symptom trialFDA declined approval; efficacy/data package deemed insufficientModest effect size on negative symptoms and reliance on a single pivotal study

Choosing the right endpoint

Primary endpoints that matter in schizophrenia trials

  • PANSS total score change — Primary efficacy standard (Positive and Negative Syndrome Scale); high placebo response complicates separation
  • BPRS — Brief Psychiatric Rating Scale; used in older trials such as the pivotal clozapine studies
  • CGI-S / CGI-I — Clinician Global Impression of severity/improvement; supportive global measure
  • Time to relapse — Key maintenance endpoint; definitions vary (hospitalization, PANSS increase, medication change), requiring long follow-up
  • Cognitive function (MCCB) — MATRICS Consensus Cognitive Battery standardizes cognitive-domain assessment, a difficult secondary endpoint

How iNGENū runs schizophrenia trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

PDF
The Complexities of Schizophrenia Clinical Trials
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Download white paper

Frequently asked questions

Schizophrenia clinical trials — FAQs

What is the primary efficacy endpoint in schizophrenia trials?
The change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score, typically over 4-6 weeks for acute studies, is the standard primary endpoint. The older Brief Psychiatric Rating Scale (BPRS) and CGI scales are also used, and maintenance trials use time to relapse.
Why is Cobenfy (xanomeline-trospium) considered a landmark approval?
Approved by the FDA in 2024, it is the first schizophrenia drug that works through a muscarinic (M1/M4) receptor mechanism rather than by blocking dopamine D2 receptors. Every prior antipsychotic depended on D2 antagonism or partial agonism, so Cobenfy represents the first genuinely new mechanistic class in decades and avoids many dopamine-related side effects.
Why do so many schizophrenia trials fail?
A persistently high and variable placebo response makes it hard for an active drug to show separation, especially for novel mechanisms. Symptom heterogeneity, subjective patient self-report, cognitive-measurement complexity, and adherence issues all add noise, and several promising mechanisms (mGluR2/3 agonists, GlyT1 inhibitors) have failed despite strong preclinical rationale.

Ready to discuss your schizophrenia trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal